We further evaluated the impact of Mtarc1 knockdown on liver fibrosis at a later time point on the GAN diet (24 wk followed by 8 weeks of biweekly siRNA treatment) with higher disease burden and found no significant effect on liver endpoints (Supplemental Information, http://links.lww.com/HC9/B878 and Supplemental Figure S6, http://links.lww.com/HC9/B878). The gene discussed is MTARC1; the disease is Hepatic fibrosis.